GlassScriptPhysician profile
Michelle D Williams
NPI 1639407018
$9,269.05
in general payments reported to CMS, 2019-2025
31 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $1,895 · 2023: $2,570 · 2024: $2,456 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,526 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,526.39 |
| Education | $179.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,698.44 | 2021-2025 | |
| Janssen Biotech, INC. | $1,084.13 | 2021-2025 | Tremfya, Stelara, Simponi |
| Leo Pharma INC. | $773.95 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $685.11 | 2021-2025 | Dupixent |
| Incyte Corporation | $660.23 | 2021-2025 | Opzelura |
| Genzyme Corporation | $659.33 | 2021-2025 | |
| Lilly USA, LLC | $470.83 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $437.42 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $435.15 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $420.86 | 2021-2025 | |
| Amgen INC. | $335.56 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $299.69 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $295.00 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $195.38 | 2021-2025 | |
| Journey Medical Corporation | $192.56 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $121.70 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $102.36 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.63 | 2023-2024 | Spevigo, Cyltezo |
| Convatec INC. | $44.19 | 2025 | |
| Biofrontera INC. | $39.79 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Inspire Medical Systems, INC. | $38.49 | 2023-2024 | Inspire |
| Botanix Sb INC | $31.96 | 2025 | Sofdra |
| Alk-Abello, INC | $26.49 | 2021-2022 | |
| Genentech USA, INC. | $23.75 | 2022 | |
| Meridian Bioscience INC. | $20.88 | 2024 | |
| Epi Health, LLC | $20.79 | 2022 | |
| Mayne Pharma Commercial LLC | $18.79 | 2023-2025 | |
| Organogenesis INC. | $18.44 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.24 | 2023 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $14.14 | 2025 | Natroba, Spinosad |
| Organon LLC | $13.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.